Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
DRESS Syndrome: Recognizing Specific Subtypes, Identifying Culprit Drug, and Differentiating from Low-Risk Morbilliform Rash
Description
This session focuses on DRESS syndrome, a severe cutaneous adverse drug reaction characterized by fever, morbilliform rash, and internal organ involvement. Led by Abe Corman and co-speakers, the discussion highlights the complexities in diagnosing and treating DRESS, emphasizing its heterogeneous presentation and different subtypes, including disparities in mortality rates based on patient demographics. Key diagnostic strategies include recognizing the latency period of symptoms, looking for the distinctive earlobe crease sign, and evaluating drug histories, particularly for known culprits. The speakers also introduce the "address score", a novel tool to identify causative drugs and highlight the importance of vigilance in older patients who may experience greater complications. Emerging therapies such as systemic corticosteroids, topical treatments, and potential immunosuppressive strategies are discussed, though the efficacy of some approaches remains controversial. The role of viral reactivation, particularly from viruses like HHV-6 and CMV, is debated, with suggestions to remain skeptical of their centrality in DRESS diagnosis. Overall, the session calls for a robust clinical evaluation, addressing not only the medication history but also the patient's overall condition, and outlines a systematic approach to treatment and management.
View moreConclusions
- DRESS syndrome presents with heterogeneous clinical manifestations necessitating careful consideration of diagnostic clues.
- An oblique earlobe crease sign shows high sensitivity and specificity for diagnosing DRESS syndrome.
- The latency period for DRESS can be as short as 15 days for certain drugs like antibiotics and iodinated contrast media.
- Research indicates that African American patients with DRESS have a higher mortality risk compared to white patients.
- Older patients with DRESS are at increased risk for cytopenias which may complicate their condition.
- Subtypes of DRESS, such as those presenting with pustulosis, may have a higher risk for recurrence.
- The ADDRESS scoring system may assist in identifying the causative drug in DRESS cases.
- A systematic review has revealed new drug classes associated with DRESS, including antipsychotics and kinase inhibitors, beyond traditional culprits like allopurinol and carbamazepine.
- Augmented intelligence tools show promise in differential diagnosis between DRESS and low-risk morbilliform rashes, with high sensitivity and specificity.
- Soria A, Bernier C, Veyrac G, Barbaud A, Puymirat E, Milpied B. Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study. J Am Acad Dermatol. 2020;82(3):606-611. doi:10.1016/j.jaad.2019.09.036
- Gilkey TW, Amigo MA, Himed S, et al. Oblique earlobe crease as a novel physical examination finding in drug reaction with eosinophilia and systemic symptoms: a retrospective study. J Eur Acad Dermatol Venereol. 2022;36(9):e739-e740. doi:10.1111/jdv.18270
- Schneider JG, Gallardo M, Fisher K, Kaffenberger BH, Korman AM. Increased mortality among African American patients with DRESS syndrome compared to White patients. Int J Dermatol. 2024;63(3):e80-e81. doi:10.1111/ijd.16988
- Hansen E, Gallardo M, Kaffenberger BH, Fisher K, Korman AM. Older DRESS patients are more likely to have cytopenias: a retrospective cohort study. Int J Dermatol. 2023;62(9):e478-e480. doi:10.1111/ijd.16642
- Hansen E, Kirven RM, Gallardo M, et al. Drug Reaction With Eosinophilia and Systemic Symptoms With Pustulosis. JAMA Dermatol. 2024;160(7):777-779. doi:10.1001/jamadermatol.2024.1082
- Hansen E, Gallardo M, Yan A, et al. Risk assessment of drugs associated with DRESS syndrome based on publication frequency: A systematic review. J Am Acad Dermatol. Published online August 3, 2024. doi:10.1016/j.jaad.2024.06.081
- Hendrixson, M., Loper, M., Fosu, N., Fisher, K., Kaffenberger, B.H., and Korman, A.M. Use of Google's Teachable Machine for Clinical Differentiation of Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome from Low-Risk Morbilliform Drug Eruptions. 2024. In process.
- Wei BM et al. J Am Acad Dermatol 2023; in press.
- Shah PN, et al. J Clin Invest. 2024 Jul 23;134(17):e178253.
- Kardaun SH et al. Br J Dermatol 2007;156:609-11.